Calan is a brand-name medication that contains the active ingredient verapamil. Verapamil belongs to the class of calcium-channel blockers and is used to manage several cardiovascular conditions. Calan is supplied as oral pill tablets in strengths of 40 mg, 80 mg, 120 mg, and 240 mg. In Hong Kong, it is available by prescription only and is regulated by the Pharmacy and Poisons Board under the Department of Health.
Verapamil blocks L-type calcium channels in the heart and blood-vessel walls. By reducing calcium entry into smooth-muscle cells, it produces three main therapeutic effects:
These actions together make verapamil useful for hypertension, stable angina, and certain arrhythmias such as supraventricular tachycardia.
Calan is approved for the following indications in Hong Kong and internationally:
The medication may also be prescribed off-label for migraine prophylaxis, but such use must follow a clinician’s assessment and is not an approved indication.
Evidence from clinical studies supports the off-label use of verapamil for migraine prevention. Randomized trials have shown a reduction in migraine frequency when verapamil is used at doses typically ranging from 120 mg to 240 mg daily. This application is not approved by the Hong Kong Department of Health and requires careful supervision because of potential cardiovascular effects.
These effects are usually mild and may improve with continued use or dose adjustment.
If any of these occur, seek medical help promptly.
Hypertension:
Start: 80 mg taken three times daily (total 240 mg/day).
Titrate: Increase by 80 mg per dose at weekly intervals up to a maximum of 480 mg/day (e.g., 160 mg three times daily).
Chronic Stable Angina:
Start: 80 mg three times daily.
Maintenance: May be increased to 120-240 mg three times daily based on symptom control.
Supraventricular Arrhythmias:
Typical regimen: 120-240 mg daily in divided doses (e.g., 80 mg twice daily).
Note: The above regimens are illustrative; the exact dose must be individualized by a qualified healthcare professional.
This article provides educational information about Calan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Calan can be combined with other antihypertensives such as ACE inhibitors or diuretics, but the combination may increase the risk of low blood pressure and should be overseen by a clinician who can adjust doses accordingly.
In Hong Kong, Calan tablets are typically round, film-coated, and marked with the dosage strength (e.g., “40 mg”) on one side and the brand logo on the other. Appearance may vary slightly between manufacturers.
Verapamil is not a controlled substance and is not screened for in standard workplace drug-testing panels. However, specialized testing could detect it if requested.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of any import restrictions imposed by the destination country’s customs regulations.
Grapefruit juice inhibits the CYP3A4 enzyme that metabolizes verapamil, potentially raising drug levels and increasing the risk of side-effects such as low blood pressure or bradycardia. It is best avoided while taking Calan.
Off-label use for migraine prophylaxis is supported by some clinical studies, but it is not approved for this purpose in Hong Kong. Use should be limited to patients who have failed first-line migraine therapies and who are monitored for cardiovascular effects.
Severe dizziness may signal excessive blood-pressure lowering. Sit or lie down, avoid sudden standing, and contact a healthcare professional promptly for evaluation and possible dose adjustment.
Herbal products such as St. John’s wort (a CYP3A4 inducer) can reduce verapamil levels, while high-dose calcium or magnesium supplements may blunt its effect. Always discuss supplements with your pharmacist.
Blood-pressure reduction can be observed within a few hours after the first dose, while full therapeutic effect for angina or arrhythmia control may require several days of consistent dosing.
Calan tablets are not scored and are formulated for whole-tablet administration to ensure consistent drug release. Splitting may alter absorption and is therefore not recommended.
